Uni-Bio Science’s Generic Diquas Accepted for NMPA Review
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
Ophthalmology
Zhaoke Ophthalmology’s Cyclosporine Eye Gel NDA Accepted by NMPA
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that the New Drug Application (NDA) for its...
Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...
Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...
Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...
Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment
US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...
Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME
China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...
Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex for Mexico
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the...
Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...
Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...
Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...
Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...
Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply...
Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment
Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...
IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis
China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...
Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu
Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...
Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU
German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...
Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from China’s National...
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy
US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake...
Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...